SRRK
Scholar Rock Holding Corporation
Price Chart
Latest Quote
$47.33
+0.38 (+0.81%)
Current Price
| Previous Close | $46.95 |
| Open | $47.27 |
| Day High | $48.08 |
| Day Low | $46.17 |
| Volume | 2,367,839 |
Stock Information
| Shares Outstanding | 119.83M |
| Total Debt | $205.67M |
| Cash Equivalents | $479.94M |
| Net Income | $-408.73M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.67B |
| EPS (TTM) | $-3.45 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.19B |
| Income | $-408.73M |
| Book/sh | $2.32 |
| Cash/sh | $4.01 |
| Employees | 289 |
Financial Ratios
| Quick Ratio | 8.41 |
| Current Ratio | 8.64 |
| Debt/Eq | 74.52 |
Returns & Margins
| ROA | -54.30% |
| ROE | -138.94% |
Ownership
| Insider Ownership | 0.79% |
| Institutional Ownership | 116.55% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -19.97 |
| P/B | 20.43 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $59.31 |
Technical Indicators
| SMA20 | $46.58 |
| SMA50 | $47.52 |
| SMA200 | $42.12 |
| RSI | 43.49 |
| ATR | 2.1339 |
| Shares Float | 91.80M |
| Short Float | 17.18% |
| Short Ratio | 12.86 |
| Volatility | 0.69 |
| Rel Volume | 2.43 |
Performance History
| Week | +5.91% |
| Month | -0.48% |
| Quarter | +4.02% |
| 6 Months | +6.79% |
| YTD | +10.58% |
| Year | +51.94% |
| 3 Years | +483.60% |
| 5 Years | +49.59% |
| 10 Years | +215.53% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $47.33 | 3,059,300 |
| 2026-06-17 | $46.95 | 1,190,100 |
| 2026-06-16 | $45.56 | 957,600 |
| 2026-06-15 | $45.92 | 824,500 |
| 2026-06-12 | $44.18 | 1,154,400 |
| 2026-06-11 | $44.69 | 976,200 |
| 2026-06-10 | $44.09 | 1,457,700 |
| 2026-06-09 | $45.58 | 994,600 |
| 2026-06-08 | $43.80 | 812,000 |
| 2026-06-05 | $44.30 | 1,153,300 |
| 2026-06-04 | $45.33 | 856,200 |
| 2026-06-03 | $44.64 | 1,135,600 |
| 2026-06-02 | $44.68 | 1,104,900 |
| 2026-06-01 | $47.39 | 1,128,800 |
| 2026-05-29 | $49.30 | 2,141,100 |
| 2026-05-28 | $49.82 | 814,300 |
| 2026-05-27 | $50.64 | 864,400 |
| 2026-05-26 | $51.51 | 2,654,400 |
| 2026-05-22 | $48.13 | 852,200 |
| 2026-05-21 | $47.72 | 1,052,000 |
| 2026-05-20 | $48.38 | 915,200 |
| 2026-05-19 | $47.56 | 873,600 |
About Scholar Rock Holding Corporation
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFÃ) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFÃ1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFÃ1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Three Biotechs That Are Top Takeover Targets
24/7 Wall St. âĸ 2026-05-18T17:55:07Z
What to Know About This Fundâs $50 Million Exit From Ascendis Pharma
Motley Fool âĸ 2026-05-14T19:05:52Z
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO
Motley Fool âĸ 2026-05-14T18:57:58Z
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700%
Motley Fool âĸ 2026-05-14T18:51:03Z
Scholar Rock Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-09T02:05:47Z
Scholar Rock (SRRK) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-08T15:30:48Z
A Look At Scholar Rock (SRRK) Valuation After Strong Multi Year Shareholder Returns
Simply Wall St. âĸ 2026-05-08T06:18:12Z
Scholar Rock (SRRK) Deepens SMA Manufacturing Footprint: Strategic Resilience Move or Regulatory Risk Signal?
Simply Wall St. âĸ 2026-04-06T12:07:09Z
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug
Zacks âĸ 2026-04-01T16:36:00Z
Scholar Rock Resubmits Apitegromab BLA for SMA, Adds Second Fill-Finish Site; FDA Decision Eyed by Sept.
MarketBeat âĸ 2026-04-01T04:03:31Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $33,193,000 |
| Operating Revenue | $0 | $0 | $0 | $33,193,000 |
| Expenses | ||||
| Interest Expense | $6,893,000 | $6,837,000 | - | - |
| Total Expenses | $384,645,000 | $252,054,000 | $171,295,000 | $167,563,000 |
| Other Income Expense | $-301,000 | $-85,000 | $5,506,000 | $-132,000 |
| Other Non Operating Income Expenses | $-301,000 | $-85,000 | $5,506,000 | $-132,000 |
| Net Non Operating Interest Income Expense | $7,007,000 | $5,845,000 | - | - |
| Interest Expense Non Operating | $6,893,000 | $6,837,000 | - | - |
| Operating Expense | $384,645,000 | $252,054,000 | $171,295,000 | $167,563,000 |
| General And Administrative Expense | $176,205,000 | $67,504,000 | $49,395,000 | $43,119,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-377,939,000 | $-246,294,000 | $-165,789,000 | $-134,502,000 |
| Net Interest Income | $7,007,000 | $5,845,000 | - | - |
| Interest Income | $13,900,000 | $12,682,000 | - | - |
| Normalized Income | $-377,939,000 | $-246,294,000 | $-165,789,000 | $-134,502,000 |
| Net Income From Continuing And Discontinued Operation | $-377,939,000 | $-246,294,000 | $-165,789,000 | $-134,502,000 |
| Total Operating Income As Reported | $-384,645,000 | $-252,054,000 | $-171,295,000 | $-134,370,000 |
| Net Income Common Stockholders | $-377,939,000 | $-246,294,000 | $-165,789,000 | $-134,502,000 |
| Net Income | $-377,939,000 | $-246,294,000 | $-165,789,000 | $-134,502,000 |
| Net Income Including Noncontrolling Interests | $-377,939,000 | $-246,294,000 | $-165,789,000 | $-134,502,000 |
| Net Income Continuous Operations | $-377,939,000 | $-246,294,000 | $-165,789,000 | $-134,502,000 |
| Pretax Income | $-377,939,000 | $-246,294,000 | $-165,789,000 | $-134,502,000 |
| Interest Income Non Operating | $13,900,000 | $12,682,000 | - | - |
| Operating Income | $-384,645,000 | $-252,054,000 | $-171,295,000 | $-134,370,000 |
| Per Share | ||||
| Diluted EPS | $-3.29 | $-2.47 | $-1.99 | $-2.26 |
| Basic EPS | $-3.29 | $-2.47 | $-1.99 | $-2.26 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-369,388,000 | $-237,520,000 | $-168,451,000 | $-131,384,000 |
| Reconciled Depreciation | $1,658,000 | $1,937,000 | $2,844,000 | $2,986,000 |
| EBITDA (Bullshit earnings) | $-369,388,000 | $-237,520,000 | $-168,451,000 | $-131,384,000 |
| EBIT | $-371,046,000 | $-239,457,000 | $-171,295,000 | $-134,370,000 |
| Diluted Average Shares | $114,701,154 | $99,838,102 | $83,347,086 | $59,611,656 |
| Basic Average Shares | $114,701,154 | $99,838,102 | $83,347,086 | $59,611,656 |
| Diluted NI Availto Com Stockholders | $-377,939,000 | $-246,294,000 | $-165,789,000 | $-134,502,000 |
| Research And Development | $208,440,000 | $184,550,000 | $121,900,000 | $124,444,000 |
| Selling General And Administration | $176,205,000 | $67,504,000 | $49,395,000 | $43,119,000 |
| Other Gand A | $176,205,000 | $67,504,000 | $49,395,000 | $43,119,000 |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $245,488,000 | $368,634,000 | $225,218,000 | $260,235,000 |
| Total Assets | $404,272,000 | $474,922,000 | $311,035,000 | $358,168,000 |
| Total Non Current Assets | $19,125,000 | $23,757,000 | $22,841,000 | $30,144,000 |
| Other Non Current Assets | $3,807,000 | $2,407,000 | $2,407,000 | $4,217,000 |
| Non Current Prepaid Assets | $3,231,000 | $2,945,000 | $4,417,000 | - |
| Current Assets | $385,147,000 | $451,165,000 | $288,194,000 | $328,024,000 |
| Prepaid Assets | $14,785,000 | $11,736,000 | $7,180,000 | $9,928,000 |
| Receivables | $2,799,000 | $2,151,000 | $1,076,000 | $2,735,000 |
| Other Receivables | $2,799,000 | $2,151,000 | $1,076,000 | $2,735,000 |
| Cash Cash Equivalents And Short Term Investments | $367,563,000 | $437,278,000 | $279,938,000 | $315,361,000 |
| Cash And Cash Equivalents | $323,527,000 | $177,878,000 | $101,855,000 | $103,275,000 |
| Goodwill And Other Intangible Assets | - | $2,395,000 | $4,074,000 | - |
| Other Intangible Assets | - | $2,395,000 | $4,074,000 | - |
| Other Current Assets | - | - | - | $12,663,000 |
| Debt | ||||
| Total Debt | $108,915,000 | $65,126,000 | $61,818,000 | $69,396,000 |
| Long Term Debt And Capital Lease Obligation | $103,365,000 | $59,352,000 | $53,076,000 | $61,544,000 |
| Long Term Debt | $99,709,000 | $50,146,000 | $48,684,000 | $49,744,000 |
| Current Debt And Capital Lease Obligation | $5,550,000 | $5,774,000 | $8,742,000 | $7,852,000 |
| Current Debt | - | - | $1,334,000 | - |
| Other Current Borrowings | - | - | $1,334,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $158,784,000 | $106,288,000 | $85,817,000 | $97,933,000 |
| Total Non Current Liabilities Net Minority Interest | $103,365,000 | $59,352,000 | $53,076,000 | $61,544,000 |
| Current Liabilities | $55,419,000 | $46,936,000 | $32,741,000 | $36,389,000 |
| Payables And Accrued Expenses | $49,869,000 | $41,162,000 | $23,914,000 | $28,315,000 |
| Payables | $10,303,000 | $10,095,000 | $3,465,000 | $3,994,000 |
| Accounts Payable | $10,303,000 | $10,095,000 | $3,465,000 | $3,994,000 |
| Other Current Liabilities | - | - | $85,000 | $222,000 |
| Current Deferred Liabilities | - | - | - | $0 |
| Other Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $245,488,000 | $368,634,000 | $225,218,000 | $260,235,000 |
| Total Equity Gross Minority Interest | $245,488,000 | $368,634,000 | $225,218,000 | $260,235,000 |
| Stockholders Equity | $245,488,000 | $368,634,000 | $225,218,000 | $260,235,000 |
| Gains Losses Not Affecting Retained Earnings | $94,000 | $160,000 | $92,000 | $-884,000 |
| Other Equity Adjustments | $94,000 | $160,000 | $92,000 | $-884,000 |
| Retained Earnings | $-1,300,654,000 | $-922,715,000 | $-676,421,000 | $-510,632,000 |
| Other | ||||
| Ordinary Shares Number | $108,461,354 | $93,823,678 | $75,979,495 | $51,672,579 |
| Share Issued | $108,461,354 | $93,823,678 | $75,979,495 | $51,672,579 |
| Tangible Book Value | $245,488,000 | $368,634,000 | $225,218,000 | $260,235,000 |
| Invested Capital | $345,197,000 | $418,780,000 | $275,236,000 | $309,979,000 |
| Working Capital | $329,728,000 | $404,229,000 | $255,453,000 | $291,635,000 |
| Capital Lease Obligations | $9,206,000 | $14,980,000 | $11,800,000 | $19,652,000 |
| Total Capitalization | $345,197,000 | $418,780,000 | $273,902,000 | $309,979,000 |
| Additional Paid In Capital | $1,545,940,000 | $1,291,095,000 | $901,471,000 | $771,699,000 |
| Capital Stock | $108,000 | $94,000 | $76,000 | $52,000 |
| Common Stock | $108,000 | $94,000 | $76,000 | $52,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $3,656,000 | $9,206,000 | $4,392,000 | $11,800,000 |
| Current Capital Lease Obligation | $5,550,000 | $5,774,000 | $7,408,000 | $7,852,000 |
| Current Accrued Expenses | $39,566,000 | $31,067,000 | $20,449,000 | $24,321,000 |
| Net PPE | $12,087,000 | $18,405,000 | $16,017,000 | $25,927,000 |
| Accumulated Depreciation | $-14,876,000 | $-13,218,000 | $-11,326,000 | $-10,231,000 |
| Gross PPE | $26,963,000 | $31,623,000 | $27,343,000 | $36,158,000 |
| Leases | $3,626,000 | $3,613,000 | $3,581,000 | $5,160,000 |
| Construction In Progress | $25,000 | $0 | - | $0 |
| Other Properties | $21,037,000 | $25,949,000 | $21,687,000 | $28,841,000 |
| Machinery Furniture Equipment | $2,275,000 | $2,061,000 | $2,075,000 | $2,157,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $44,036,000 | $259,400,000 | $178,083,000 | $212,086,000 |
| Current Deferred Revenue | - | - | - | $0 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-300,637,000 | $-201,047,000 | $-145,297,000 | $-133,758,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-300,035,000 | $-200,949,000 | $-145,226,000 | $-132,694,000 |
| Cash Flow From Continuing Operating Activities | $-300,035,000 | $-200,949,000 | $-145,226,000 | $-132,694,000 |
| Operating Gains Losses | - | - | $11,000 | $33,000 |
| Investing Activities | ||||
| Capital Expenditure | $-602,000 | $-98,000 | $-71,000 | $-1,064,000 |
| Investing Cash Flow | $218,687,000 | $-76,056,000 | $41,141,000 | $-171,698,000 |
| Cash Flow From Continuing Investing Activities | $218,687,000 | $-76,056,000 | $41,141,000 | $-171,698,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $91,660,000 | $324,414,000 | $97,709,000 | $195,315,000 |
| Financing Cash Flow | $228,399,000 | $353,028,000 | $102,574,000 | $194,832,000 |
| Cash Flow From Continuing Financing Activities | $228,399,000 | $353,028,000 | $102,574,000 | $194,832,000 |
| Net Common Stock Issuance | $91,660,000 | $324,414,000 | $97,709,000 | $195,315,000 |
| Common Stock Issuance | $91,660,000 | $324,414,000 | $97,709,000 | $195,315,000 |
| Net Other Financing Charges | - | $-125,000 | $3,000 | $-975,000 |
| Other | ||||
| Repayment Of Debt | $-25,520,000 | $0 | $0 | $-975,000 |
| Issuance Of Debt | $74,660,000 | $0 | - | $0 |
| Interest Paid Supplemental Data | $6,066,000 | $6,617,000 | $6,399,000 | $4,372,000 |
| End Cash Position | $327,334,000 | $180,285,000 | $104,262,000 | $105,773,000 |
| Beginning Cash Position | $180,285,000 | $104,262,000 | $105,773,000 | $215,333,000 |
| Effect Of Exchange Rate Changes | $-2,000 | $0 | - | - |
| Changes In Cash | $147,051,000 | $76,023,000 | $-1,511,000 | $-109,560,000 |
| Proceeds From Stock Option Exercised | $87,599,000 | $28,739,000 | $4,862,000 | $492,000 |
| Net Issuance Payments Of Debt | $49,140,000 | $0 | $0 | $0 |
| Net Long Term Debt Issuance | $49,140,000 | $0 | $0 | $0 |
| Long Term Debt Payments | $-25,520,000 | $0 | $0 | $-975,000 |
| Long Term Debt Issuance | $74,660,000 | $0 | - | $0 |
| Net Investment Purchase And Sale | $219,289,000 | $-75,958,000 | $41,199,000 | $-170,634,000 |
| Sale Of Investment | $317,298,000 | $217,200,000 | $332,000,000 | $130,000,000 |
| Purchase Of Investment | $-98,009,000 | $-293,158,000 | $-290,801,000 | $-300,634,000 |
| Net PPE Purchase And Sale | $-602,000 | $-98,000 | $-58,000 | $-1,064,000 |
| Purchase Of PPE | $-602,000 | $-98,000 | $-71,000 | $-1,064,000 |
| Change In Working Capital | $-1,050,000 | $6,594,000 | $-10,614,000 | $-34,389,000 |
| Change In Other Current Liabilities | $-5,774,000 | $-6,271,000 | $-7,990,000 | $-7,415,000 |
| Change In Other Current Assets | $-286,000 | $1,472,000 | $-2,698,000 | $-97,000 |
| Change In Payables And Accrued Expense | $8,707,000 | $17,163,000 | $-4,456,000 | $6,638,000 |
| Change In Accrued Expense | $8,499,000 | $10,533,000 | $-3,927,000 | $6,889,000 |
| Change In Payable | $208,000 | $6,630,000 | $-529,000 | $-251,000 |
| Change In Account Payable | $208,000 | $6,630,000 | $-529,000 | $-251,000 |
| Change In Prepaid Assets | $-3,697,000 | $-5,770,000 | $4,530,000 | $-322,000 |
| Other Non Cash Items | $5,685,000 | $5,477,000 | $7,400,000 | $7,619,000 |
| Stock Based Compensation | $75,600,000 | $36,628,000 | $27,142,000 | $27,701,000 |
| Amortization Of Securities | $-3,989,000 | $-5,291,000 | $-6,220,000 | $-2,142,000 |
| Depreciation Amortization Depletion | $1,658,000 | $1,937,000 | $2,844,000 | $2,986,000 |
| Depreciation And Amortization | $1,658,000 | $1,937,000 | $2,844,000 | $2,986,000 |
| Net Income From Continuing Operations | $-377,939,000 | $-246,294,000 | $-165,789,000 | $-134,502,000 |
| Sale Of PPE | - | $0 | $13,000 | $0 |
| Gain Loss On Sale Of PPE | - | $0 | $11,000 | $33,000 |
| Change In Other Working Capital | - | - | - | $-33,193,000 |
| Change In Receivables | - | - | - | - |
| Changes In Account Receivables | - | - | - | - |
Fetched: 2026-06-15